title: Pediatric non alcoholic fatty liver disease: more on novel treatment targets.
abstract: The mainstay treatment of non alcoholic fatty liver disease (NAFLD) based on weight loss and/or lifestyle changes is most often unsuccessful at all ages, thus requiring the implementation of pharmacological strategies. Targeting insulin resistance and oxidative stress has recently proven unsatisfactory. Among a number of proposed innovative approaches targeting novel pathomechanisms, probiotics appear an interesting and reasonable option acting on gut-liver axis malfunction through the modulation of diet-driven, obesogenic, and inflammatory intestinal microbiota.A combined multiple pharmacological therapy directed simultaneously towards novel and old pathomechanisms (including, e.g., insulin resistance, oxidative stress, gut-liver axis, apoptosis) along with lifestyle interventions however might be necessary both in adult and pediatric NAFLD therapy.
authors.affiliation: Department of Medicine and Surgery, University of Salerno, Via S, Allende, 84081 Baronissi -Salerno, Italy. pvajro@unisa.it
authors.forename: Pietro
authors.initials: P
authors.lastname: Vajro
authors.forename: Giulia
authors.initials: G
authors.lastname: Paolella
authors.forename: Marco
authors.initials: M
authors.lastname: Poeta
authors.forename: Cristina
authors.initials: C
authors.lastname: Pizza
authors.forename: Maria
authors.initials: M
authors.lastname: Sangermano
authors.forename: Grazia
authors.initials: G
authors.lastname: Massa
mesh_terms: D002648:Child; D003131:Combined Modality Therapy; D005234:Fatty Liver / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D008019:Life Style; D065626:Non-alcoholic Fatty Liver Disease; D019936:Probiotics / Q000627:therapeutic use*